BIOMARKER DISCOVERIES AND POTENTIAL BIOMARKERS IN LUNG CANCER : A NARRATIVE REVIEW
DOI:
https://doi.org/10.23917/ujp.v2i4.167Abstract
Lung cancer is the second most common cause of death worldwide after breast cancer. This is associated with late diagnosis, which reduces the survival rate. Early diagnosis is one approach that may be employed to improve outcome for the patient with lung cancer. When a small level of cancer is present in the body, a biomarker can be utilized as a diagnostic marker. Liquid biopsy is minimal invasive which can be done to obtain multi-biomarkers in lung cancer. In this article, we will discuss and explore about potential biomarkers for lung cancer early diagnosis.
Downloads
References
Akman, B., Erkek-Ozhan, S., 2022. Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer, in: Frimley Park Hospital, Frimley Health NHS Foundation Trust, Camberley, UK, Barber, N. (Eds.), Urologic Cancers. Exon Publications, pp. 45–60. https://doi.org/10.36255/exon-publications-urologic-cancers-bladder-cancer-epigenetics
Amintas, S., Vendrely, V., Dupin, C., Buscail, L., Laurent, C., Bournet, B., Merlio, J.-P., Bedel, A., Moreau-Gaudry, F., Boutin, J., Dabernat, S., Buscail, E., 2021. Next-Generation Cancer Biomarkers: Extracellular Vesicle DNA as a Circulating Surrogate of Tumor DNA. Front. Cell Dev. Biol. 8, 622048. https://doi.org/10.3389/fcell.2020.622048
Bannister, A.J., Kouzarides, T., 2011. Regulation of chromatin by histone modifications. Cell Res. 21, 381–395. https://doi.org/10.1038/cr.2011.22
Barefoot, M.E., Loyfer, N., Kiliti, A.J., McDeed, A.P., Kaplan, T., Wellstein, A., 2021. Detection of Cell Types Contributing to Cancer From Circulating, Cell-Free Methylated DNA. Front. Genet. 12, 671057. https://doi.org/10.3389/fgene.2021.671057
Bartel, D.P., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297. https://doi.org/10.1016/S0092-8674(04)00045-5
Baylin, S.B., Jones, P.A., 2011. A decade of exploring the cancer epigenome — biological and translational implications. Nat. Rev. Cancer 11, 726–734. https://doi.org/10.1038/nrc3130
Benevolenskaya, E.V., Islam, A.B.M.M.K., Ahsan, H., Kibriya, M.G., Jasmine, F., Wolff, B., Al-Alem, U., Wiley, E., Kajdacsy-Balla, A., Macias, V., Rauscher, G.H., 2016. DNA methylation and hormone receptor status in breast cancer. Clin. Epigenetics 8, 17. https://doi.org/10.1186/s13148-016-0184-7
Bentwich, I., Avniel, A., Karov, Y., Aharonov, R., Gilad, S., Barad, O., Barzilai, A., Einat, P., Einav, U., Meiri, E., Sharon, E., Spector, Y., Bentwich, Z., 2005. Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet. 37, 766–770. https://doi.org/10.1038/ng1590
Bhangu, J.S., Taghizadeh, H., Braunschmid, T., Bachleitner-Hofmann, T., Mannhalter, C., 2017. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden. Surg. Oncol. 26, 395–401. https://doi.org/10.1016/j.suronc.2017.08.001
Biomarkers Definitions Working Group, 2001. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95. https://doi.org/10.1067/mcp.2001.113989
Brejc, K., Bian, Q., Uzawa, S., Wheeler, B.S., Anderson, E.C., King, D.S., Kranzusch, P.J., Preston, C.G., Meyer, B.J., 2017. Dynamic Control of X Chromosome Conformation and Repression by a Histone H4K20 Demethylase. Cell 171, 85-102.e23. https://doi.org/10.1016/j.cell.2017.07.041
Bryan, E.J., Jokubaitis, V.J., Chamberlain, N.L., Baxter, S.W., Dawson, E., Choong, D.Y.H., Campbell, I.G., 2002. Mutation analysis ofEP300 in colon, breast and ovarian carcinomas. Int. J. Cancer 102, 137–141. https://doi.org/10.1002/ijc.10682
Buzdin, A., Sorokin, M., Garazha, A., Glusker, A., Aleshin, A., Poddubskaya, E., Sekacheva, M., Kim, E., Gaifullin, N., Giese, A., Seryakov, A., Rumiantsev, P., Moshkovskii, S., Moiseev, A., 2020. RNA sequencing for research and diagnostics in clinical oncology. Semin. Cancer Biol. 60, 311–323. https://doi.org/10.1016/j.semcancer.2019.07.010
Cao, W., Lee, H., Wu, W., Zaman, A., McCorkle, S., Yan, M., Chen, J., Xing, Q., Sinnott-Armstrong, N., Xu, H., Sailani, M.R., Tang, W., Cui, Y., liu, J., Guan, H., Lv, P., Sun, X., Sun, L., Han, P., Lou, Y., Chang, J., Wang, J., Gao, Y., Guo, J., Schenk, G., Shain, A.H., Biddle, F.G., Collisson, E., Snyder, M., Bivona, T.G., 2020. Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nat. Commun. 11, 3675. https://doi.org/10.1038/s41467-020-17227-z
Cao, X., Tang, Q., Holland-Letz, T., Gündert, M., Cuk, K., Schott, S., Heil, J., Golatta, M., Sohn, C., Schneeweiss, A., Burwinkel, B., 2018. Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals. Int. J. Mol. Sci. 19, 900. https://doi.org/10.3390/ijms19030900
Chan, J.C., Maze, I., 2020. Nothing Is Yet Set in (Hi)stone: Novel Post-Translational Modifications Regulating Chromatin Function. Trends Biochem. Sci. 45, 829–844. https://doi.org/10.1016/j.tibs.2020.05.009
Chan, K.C.A., Lai, P.B.S., Mok, T.S.K., Chan, H.L.Y., Ding, C., Yeung, S.W., Lo, Y.M.D., 2008. Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma. Clin. Chem. 54, 1528–1536. https://doi.org/10.1373/clinchem.2008.104653
Chan, K.C.A., Woo, J.K.S., King, A., Zee, B.C.Y., Lam, W.K.J., Chan, S.L., Chu, S.W.I., Mak, C., Tse, I.O.L., Leung, S.Y.M., Chan, G., Hui, E.P., Ma, B.B.Y., Chiu, R.W.K., Leung, S.-F., van Hasselt, A.C., Chan, A.T.C., Lo, Y.M.D., 2017. Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer. N. Engl. J. Med. 377, 513–522. https://doi.org/10.1056/NEJMoa1701717
Chen, C.-Y., Wu, J.-J., Lin, Y.-J., Hsu, C.-H., Hu, J.-M., Chang, P.-K., Sun, C.-A., Yang, T., Su, J.-Q., Chou, Y.-C., 2022. Significance of Hypermethylation of Tumor-Suppressor Genes PTGER4 and ZNF43 at CpG Sites in the Prognosis of Colorectal Cancer. Int. J. Mol. Sci. 23, 10225. https://doi.org/10.3390/ijms231810225
Chen, M., Zhao, H., 2019. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum. Genomics 13, 34. https://doi.org/10.1186/s40246-019-0220-8
Chen, Yating, Guo, W., Fan, J., Chen, Yuqing, Zhang, X., Chen, X., Luo, P., 2017. The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor. Cancer Manag. Res. Volume 9, 801–811. https://doi.org/10.2147/CMAR.S151235
Chen, Z., Hong, L., Pan, F., Jiang, H., Zhang, L., Liu, Y., Cai, C., Hua, C., Luo, X., Sun, J., 2016. miR-125b inhibited epithelialal–mesenchymal transition of triple-negative breast cancer by targeting MAP2K7. OncoTargets Ther. 2639. https://doi.org/10.2147/OTT.S102713
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M.L., Rehman, M., Walther, T.C., Olsen, J.V., Mann, M., 2009. Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions. Science 325, 834–840. https://doi.org/10.1126/science.1175371
Cloos, P.A.C., Christensen, J., Agger, K., Helin, K., 2008. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev. 22, 1115–1140. https://doi.org/10.1101/gad.1652908
Coyle, Y.M., Xie, X.-J., Lewis, C.M., Bu, D., Milchgrub, S., Euhus, D.M., 2007. Role of Physical Activity in Modulating Breast Cancer Risk as Defined by APC and RASSF1A Promoter Hypermethylation in Nonmalignant Breast Tissue. Cancer Epidemiol. Biomarkers Prev. 16, 192–196. https://doi.org/10.1158/1055-9965.EPI-06-0700
Creyghton, M.P., Cheng, A.W., Welstead, G.G., Kooistra, T., Carey, B.W., Steine, E.J., Hanna, J., Lodato, M.A., Frampton, G.M., Sharp, P.A., Boyer, L.A., Young, R.A., Jaenisch, R., 2010. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. 107, 21931–21936. https://doi.org/10.1073/pnas.1016071107
Das, P.M., Singal, R., 2004. DNA Methylation and Cancer. J. Clin. Oncol. 22, 4632–4642. https://doi.org/10.1200/JCO.2004.07.151
Das, V., Kalita, J., Pal, M., 2017. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges. Biomed. Pharmacother. 87, 8–19. https://doi.org/10.1016/j.biopha.2016.12.064
Dawson, M.A., Kouzarides, T., 2012. Cancer Epigenetics: From Mechanism to Therapy. Cell 150, 12–27. https://doi.org/10.1016/j.cell.2012.06.013
Dlamini, Z., Mbele, M., Makhafola, T.J., Hull, R., Marima, R., 2021. HIV-Associated Cancer Biomarkers: A Requirement for Early Diagnosis. Int. J. Mol. Sci. 22, 8127. https://doi.org/10.3390/ijms22158127
El Messaoudi, S., Mouliere, F., Du Manoir, S., Bascoul-Mollevi, C., Gillet, B., Nouaille, M., Fiess, C., Crapez, E., Bibeau, F., Theillet, C., Mazard, T., Pezet, D., Mathonnet, M., Ychou, M., Thierry, A.R., 2016. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clin. Cancer Res. 22, 3067–3077. https://doi.org/10.1158/1078-0432.CCR-15-0297
Esteve-Puig, R., Bueno-Costa, A., Esteller, M., 2020. Writers, readers and erasers of RNA modifications in cancer. Cancer Lett. 474, 127–137. https://doi.org/10.1016/j.canlet.2020.01.021
Feng, W., Orlandi, R., Zhao, N., Carcangiu, M.L., Tagliabue, E., Xu, J., Bast, R.C., Yu, Y., 2010. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer 10, 378. https://doi.org/10.1186/1471-2407-10-378
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D.M., Piñeros, M., Znaor, A., Bray, F., 2021. Cancer statistics for the year 2020: An overview. Int. J. Cancer 149, 778–789. https://doi.org/10.1002/ijc.33588
Fischer, J.R., Ohnmacht, U., Rieger, N., Zemaitis, M., Stoffregen, C., Manegold, C., Lahm, H., 2007.
Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer 56, 115–123. https://doi.org/10.1016/j.lungcan.2006.11.016
Fraga, M.F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., Iyer, N.G., Pérez-Rosado, A., Calvo, E., Lopez, J.A., Cano, A., Calasanz, M.J., Colomer, D., Piris, M.Á., Ahn, N., Imhof, A., Caldas, C., Jenuwein, T., Esteller, M., 2005. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37, 391–400. https://doi.org/10.1038/ng1531
Gagliardi, M., Strazzullo, M., Matarazzo, M.R., 2018. DNMT3B Functions: Novel Insights From Human Disease. Front. Cell Dev. Biol. 6, 140. https://doi.org/10.3389/fcell.2018.00140
Galamb, O., Kalmár, A., Péterfia, B., Csabai, I., Bodor, A., Ribli, D., Krenács, T., Patai, Á.V., Wichmann, B., Barták, B.K., Tóth, K., Valcz, G., Spisák, S., Tulassay, Z., Molnár, B., 2016. Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer. Epigenetics 11, 588–602. https://doi.org/10.1080/15592294.2016.1190894
García-Saenz, J.A., Ayllón, P., Laig, M., Acosta-Eyzaguirre, D., García-Esquinas, M., Montes, M., Sanz, J., Barquín, M., Moreno, F., Garcia-Barberan, V., Díaz-Rubio, E., Caldes, T., Romero, A., 2017. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer 17, 210. https://doi.org/10.1186/s12885-017-3185-9
Geng, Q., Fan, T., Zhang, B., Wang, W., Xu, Y., Hu, H., 2014. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer. Respir. Res. 15, 149. https://doi.org/10.1186/s12931-014-0149-3
Ghosh, Amit, Ghosh, Alip, Datta, Somenath, Dasgupta, D., Das, S., Ray, S., Gupta, S., Datta, Simanti, Chowdhury, A., Chatterjee, R., Mohapatra, S.K., Banerjee, S., 2016. Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma: MicroRNA as biomarker for HBV-infected hepatocellular carcinoma. Int. J. Cancer 138, 2732–2744. https://doi.org/10.1002/ijc.29999
Goossens, N., Nakagawa, S., Sun, X., Hoshida, Y., 2015. Cancer biomarker discovery and validation. Transl. Cancer Res. 4, 256–269. https://doi.org/10.3978/j.issn.2218-676X.2015.06.04
Grady, W.M., Yu, M., Markowitz, S.D., 2021. Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer. Gastroenterology 160, 690–709. https://doi.org/10.1053/j.gastro.2020.09.058
Gujral, P., Mahajan, V., Lissaman, A.C., Ponnampalam, A.P., 2020. Histone acetylation and the role of histone deacetylases in normal cyclic endometrium. Reprod. Biol. Endocrinol. 18, 84. https://doi.org/10.1186/s12958-020-00637-5
Hake, S.B., Garcia, B.A., Kauer, M., Baker, S.P., Shabanowitz, J., Hunt, D.F., Allis, C.D., 2005. Serine 31 phosphorylation of histone variant H3.3 is specific to regions bordering centromeres in metaphase chromosomes. Proc. Natl. Acad. Sci. 102, 6344–6349. https://doi.org/10.1073/pnas.0502413102
He, J.H., Han, Z.P., Luo, J.G., Jiang, J.W., Zhou, J.B., Chen, W.M., Lv, Y.B., He, M.L., Zheng, L., Li, Y.G., Zuo, J.D., 2020. Hsa_Circ_0007843 Acts as a mIR-518c-5p Sponge to Regulate the Migration and Invasion of Colon Cancer SW480 Cells. Front. Genet. 11, 9. https://doi.org/10.3389/fgene.2020.00009
Herath, S., Sadeghi Rad, H., Radfar, P., Ladwa, R., Warkiani, M., O’Byrne, K., Kulasinghe, A., 2022. The Role of Circulating Biomarkers in Lung Cancer. Front. Oncol. 11, 801269. https://doi.org/10.3389/fonc.2021.801269
Hiddinga, B., Zwaenepoel, K., Janssens, A., Van Meerbeeck, J., Pauwels, P., 2022. Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)? Oncotarget 13, 800–809. https://doi.org/10.18632/oncotarget.28240
Hoang, P.H., Landi, M.T., 2022. DNA Methylation in Lung Cancer: Mechanisms and Associations with Histological Subtypes, Molecular Alterations, and Major Epidemiological Factors. Cancers 14, 961. https://doi.org/10.3390/cancers14040961
Hon, G.C., Hawkins, R.D., Caballero, O.L., Lo, C., Lister, R., Pelizzola, M., Valsesia, A., Ye, Z., Kuan, S., Edsall, L.E., Camargo, A.A., Stevenson, B.J., Ecker, J.R., Bafna, V., Strausberg, R.L., Simpson, A.J., Ren, B., 2012. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res. 22, 246–258. https://doi.org/10.1101/gr.125872.111
Hussen, B.M., Abdullah, S.T., Salihi, A., Sabir, D.K., Sidiq, K.R., Rasul, M.F., Hidayat, H.J., Ghafouri-Fard, S., Taheri, M., Jamali, E., 2022. The emerging roles of NGS in clinical oncology and personalized medicine. Pathol. - Res. Pract. 230, 153760. https://doi.org/10.1016/j.prp.2022.153760
Hwang, J.-A., Kim, Y., Hong, S.-H., Lee, J., Cho, Y.G., Han, J.-Y., Kim, Y.-H., Han, J., Shim, Y.M., Lee, Y.-S., Kim, D.-H., 2013. Epigenetic Inactivation of Heparan Sulfate (Glucosamine) 3-O-Sulfotransferase 2 in Lung Cancer and Its Role in Tumorigenesis. PLoS ONE 8, e79634. https://doi.org/10.1371/journal.pone.0079634
Iorio, M.V., Croce, C.M., 2012. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 4, 143–159. https://doi.org/10.1002/emmm.201100209
Japanese Society of Medical Oncology, Japan Society of Clinical Oncology, Japanese Cancer Association, Naito, Y., Aburatani, H., Amano, T., Baba, E., Furukawa, T., Hayashida, T., Hiyama, E., Ikeda, S., Kanai, M., Kato, M., Kinoshita, I., Kiyota, N., Kohno, T., Kohsaka, S., Komine, K., Matsumura, I., Miura, Y., Nakamura, Y., Natsume, A., Nishio, K., Oda, K., Oda, N., Okita, N., Oseto, K., Sunami, K., Takahashi, H., Takeda, M., Tashiro, S., Toyooka, S., Ueno, H., Yachida, S., Yoshino, T., Tsuchihara, K., 2021. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int. J. Clin. Oncol. 26, 233–283. https://doi.org/10.1007/s10147-020-01831-6
Jiang, N., Reich, C.F., Pisetsky, D.S., 2003. Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells. Blood 102, 2243–2250. https://doi.org/10.1182/blood-2002-10-3312
Jiang, P., Sun, K., Tong, Y.K., Cheng, S.H., Cheng, T.H.T., Heung, M.M.S., Wong, J., Wong, V.W.S., Chan, H.L.Y., Chan, K.C.A., Lo, Y.M.D., Chiu, R.W.K., 2018. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proc. Natl. Acad. Sci. 115. https://doi.org/10.1073/pnas.1814616115
Jones, P.A., Issa, J.-P.J., Baylin, S., 2016. Targeting the cancer epigenome for therapy. Nat. Rev. Genet. 17, 630–641. https://doi.org/10.1038/nrg.2016.93
Juergens, R.A., Wrangle, J., Vendetti, F.P., Murphy, S.C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C.M., Franco, N., Lee, B., Tsai, S., Delgado, I.E., Rudek, M.A., Belinsky, S.A., Herman, J.G., Baylin, S.B., Brock, M.V., Rudin, C.M., 2011. Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer. Cancer Discov. 1, 598–607. https://doi.org/10.1158/2159-8290.CD-11-0214
Kamel, H.F.M., Al-Amodi, H.S.B., 2016. Role of Biomarkers in Medicine, in: Wang, M., Witzmann, F.A. (Eds.), Role of Biomarkers in Medicine. InTech. https://doi.org/10.5772/62421
Kanzi, A.M., San, J.E., Chimukangara, B., Wilkinson, E., Fish, M., Ramsuran, V., de Oliveira, T., 2020. Next Generation Sequencing and Bioinformatics Analysis of Family Genetic Inheritance. Front. Genet. 11, 544162. https://doi.org/10.3389/fgene.2020.544162
Keller, L., Belloum, Y., Wikman, H., Pantel, K., 2021. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br. J. Cancer 124, 345–358. https://doi.org/10.1038/s41416-020-01047-5
Khomiak, A., Brunner, M., Kordes, M., Lindblad, S., Miksch, R.C., Öhlund, D., Regel, I., 2020. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers 12, 3234. https://doi.org/10.3390/cancers12113234
Kim, J., Guermah, M., McGinty, R.K., Lee, J.-S., Tang, Z., Milne, T.A., Shilatifard, A., Muir, T.W., Roeder, R.G., 2009. RAD6-Mediated Transcription-Coupled H2B Ubiquitylation Directly Stimulates H3K4 Methylation in Human Cells. Cell 137, 459–471. https://doi.org/10.1016/j.cell.2009.02.027
Kim, V.N., Han, J., Siomi, M.C., 2009. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 10, 126–139. https://doi.org/10.1038/nrm2632
Kishimoto, M., Kohno, T., Okudela, K., Otsuka, A., Sasaki, H., Tanabe, C., Sakiyama, T., Hirama, C., Kitabayashi, I., Minna, J.D., Takenoshita, S., Yokota, J., 2005. Mutations and deletions of the CBP gene in human lung cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 11, 512–519.
Kloten, V., Becker, B., Winner, K., Schrauder, M.G., Fasching, P.A., Anzeneder, T., Veeck, J., Hartmann, A., Knüchel, R., Dahl, E., 2013. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 15, R4. https://doi.org/10.1186/bcr3375
Kosaka, N., Iguchi, H., Ochiya, T., 2010. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101, 2087–2092. https://doi.org/10.1111/j.1349-7006.2010.01650.x
Kustanovich, A., Schwartz, R., Peretz, T., Grinshpun, A., 2019. Life and death of circulating cell-free DNA. Cancer Biol. Ther. 20, 1057–1067. https://doi.org/10.1080/15384047.2019.1598759
Lawrence, M., Daujat, S., Schneider, R., 2016. Lateral Thinking: How Histone Modifications Regulate Gene Expression. Trends Genet. 32, 42–56. https://doi.org/10.1016/j.tig.2015.10.007
Leon, S.A., Shapiro, B., Sklaroff, D.M., Yaros, M.J., 1977. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646–650.
Levenson, V.V., 2004. Biomarkers: diagnostic highlights and surrogate end points. Pharmacogenomics 5, 459–461. https://doi.org/10.1517/14622416.5.5.459
Leygo, C., Williams, M., Jin, H.C., Chan, M.W.Y., Chu, W.K., Grusch, M., Cheng, Y.Y., 2017. DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer. Dis. Markers 2017, 1–13. https://doi.org/10.1155/2017/3726595
Li, J., Guan, X., Fan, Z., Ching, L.-M., Li, Y., Wang, X., Cao, W.-M., Liu, D.-X., 2020. Non-Invasive Biomarkers for Early Detection of Breast Cancer. Cancers 12, 2767. https://doi.org/10.3390/cancers12102767
Li, Y., Zhang, Y., Qiu, F., Qiu, Z., 2011. Proteomic identification of exosomal LRG1: A potential urinary biomarker for detecting NSCLC. ELECTROPHORESIS 32, 1976–1983. https://doi.org/10.1002/elps.201000598
Li, Z., Guo, X., Wu, Y., Li, S., Yan, J., Peng, L., Xiao, Z., Wang, S., Deng, Z., Dai, L., Yi, W., Xia, K., Tang, L., Wang, J., 2015. Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients. Breast Cancer Res. Treat. 149, 767–779. https://doi.org/10.1007/s10549-015-3276-8
Liang, R., Li, X., Li, W., Zhu, X., Li, C., 2021. DNA methylation in lung cancer patients: Opening a “window of life” under precision medicine. Biomed. Pharmacother. 144, 112202. https://doi.org/10.1016/j.biopha.2021.112202
Lin, C., Liu, X., Zheng, B., Ke, R., Tzeng, C.-M., 2021. Liquid Biopsy, ctDNA Diagnosis through NGS. Life 11, 890. https://doi.org/10.3390/life11090890
Litt, M., Qiu, Y., Huang, S., 2009. Histone arginine methylations: their roles in chromatin dynamics and transcriptional regulation. Biosci. Rep. 29, 131–141. https://doi.org/10.1042/BSR20080176
Liu, C., Eng, C., Shen, J., Lu, Y., Takata, Y., Mehdizadeh, A., Chang, G.J., Rodriguez-Bigas, M.A., Li, Y., Chang, P., Mao, Y., Hassan, M.M., Wang, F., Li, D., 2016. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget 7, 76250–76260. https://doi.org/10.18632/oncotarget.12841
Liu, W., Han, F., Huang, Y., Chen, H., Chen, J., Wang, D., Jiang, X., Yin, L., Cao, J., Liu, J., 2018. TMEM196 hypermethylation as a novel diagnostic and prognostic biomarker for lung cancer. Mol. Carcinog. mc.22942. https://doi.org/10.1002/mc.22942
Lu, S., Kong, H., Hou, Y., Ge, D., Huang, W., Ou, J., Yang, D., Zhang, L., Wu, G., Song, Y., Zhang, X., Zhai, C., Wang, Q., Zhu, H., Wu, Y., Bai, C., 2018. Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. Lung Cancer 123, 44–51. https://doi.org/10.1016/j.lungcan.2018.06.027
Lu, X., Simon, M.D., Chodaparambil, J.V., Hansen, J.C., Shokat, K.M., Luger, K., 2008. The effect of H3K79 dimethylation and H4K20 trimethylation on nucleosome and chromatin structure. Nat. Struct. Mol. Biol. 15, 1122–1124. https://doi.org/10.1038/nsmb.1489
Magdalena Derbis, M.S., 2012. Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. Gynecol. Obstet. s4. https://doi.org/10.4172/2161-0932.S4-003
Mahindroo, N., Punchihewa, C., Fujii, N., 2009. Hedgehog-Gli signaling pathway inhibitors as anticancer agents. J. Med. Chem. 52, 3829–3845. https://doi.org/10.1021/jm801420y
Mansour, S.A., Farhat, A.A., Abd El-Zaher, A.H., Bediwy, A.S., Abdou, S.M., Al Saka, A.A., Zidan, A.A.A., 2020. MicroRNA genetic signature in non-small cell lung cancer (NSCLC) Egyptian patients. Egypt. J. Bronchol. 14, 20. https://doi.org/10.1186/s43168-020-00021-2
Margueron, R., Reinberg, D., 2011. The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349. https://doi.org/10.1038/nature09784
Martin, B.J.E., Brind’Amour, J., Kuzmin, A., Jensen, K.N., Liu, Z.C., Lorincz, M., Howe, L.J., 2021. Transcription shapes genome-wide histone acetylation patterns. Nat. Commun. 12, 210. https://doi.org/10.1038/s41467-020-20543-z
Matrone, A., Torregrossa, L., Sensi, E., Cappellani, D., Baronti, W., Ciampi, R., Molinaro, E., Ugolini, C., Aghababyan, A., De Napoli, L., Latrofa, F., Materazzi, G., Basolo, F., Vitti, P., Elisei, R., 2019. The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy. Front. Oncol. 9, 1390. https://doi.org/10.3389/fonc.2019.01390
Meeks, J.J., Shilatifard, A., 2017. Multiple Roles for the MLL/COMPASS Family in the Epigenetic Regulation of Gene Expression and in Cancer. Annu. Rev. Cancer Biol. 1, 425–446. https://doi.org/10.1146/annurev-cancerbio-050216-034333
Menon, A., Abd-Aziz, N., Khalid, K., Poh, C.L., Naidu, R., 2022. miRNA: A Promising Therapeutic Target in Cancer. Int. J. Mol. Sci. 23, 11502. https://doi.org/10.3390/ijms231911502
Möller, A., Lobb, R.J., 2020. The evolving translational potential of small extracellular vesicles in cancer. Nat. Rev. Cancer 20, 697–709. https://doi.org/10.1038/s41568-020-00299-w
Moon, P.-G., Lee, J.-E., Cho, Y.-E., Lee, S.J., Chae, Y.S., Jung, J.H., Kim, I.-S., Park, H.Y., Baek, M.-C., 2016. Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer. Oncotarget 7, 40189–40199. https://doi.org/10.18632/oncotarget.9561
Mouliere, F., Robert, B., Arnau Peyrotte, E., Del Rio, M., Ychou, M., Molina, F., Gongora, C., Thierry, A.R., 2011. High Fragmentation Characterizes Tumour-Derived Circulating DNA. PLoS ONE 6, e23418. https://doi.org/10.1371/journal.pone.0023418
Muhammad, I.I., Kong, S.L., Akmar Abdullah, S.N., Munusamy, U., 2019. RNA-seq and ChIP-seq as Complementary Approaches for Comprehension of Plant Transcriptional Regulatory Mechanism. Int. J. Mol. Sci. 21, 167. https://doi.org/10.3390/ijms21010167
Muinao, T., Deka Boruah, H.P., Pal, M., 2018. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review. Exp. Cell Res. 362, 1–10. https://doi.org/10.1016/j.yexcr.2017.10.018
Müller, D., Győrffy, B., 2022. DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer. Biochim. Biophys. Acta BBA - Rev. Cancer 1877, 188722. https://doi.org/10.1016/j.bbcan.2022.188722
Mundade, R., Ozer, H.G., Wei, H., Prabhu, L., Lu, T., 2014. Role of ChIP-seq in the discovery of transcription factor binding sites, differential gene regulation mechanism, epigenetic marks and beyond. Cell Cycle 13, 2847–2852. https://doi.org/10.4161/15384101.2014.949201
Muraoka, M., Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., Shitara, N., Chong, J.M., Iwama, T., Miyaki, M., 1996. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12, 1565–1569.
Nguyen, A.T., Zhang, Y., 2011. The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 25, 1345–1358. https://doi.org/10.1101/gad.2057811
Ong, Q., Sakashita, S., Hanawa, E., Kaneko, N., Noguchi, M., Muratani, M., 2021. Integrative RNA-Seq and H3 Trimethylation ChIP-Seq Analysis of Human Lung Cancer Cells Isolated by Laser-Microdissection. Cancers 13, 1719. https://doi.org/10.3390/cancers13071719
Osmani, L., Askin, F., Gabrielson, E., Li, Q.K., 2018. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin. Cancer Biol. 52, 103–109. https://doi.org/10.1016/j.semcancer.2017.11.019
Otmani, K., Rouas, R., Lewalle, P., 2022. OncomiRs as noncoding RNAs having functions in cancer: Their role in immune suppression and clinical implications. Front. Immunol. 13, 913951. https://doi.org/10.3389/fimmu.2022.913951
Pal, M., Muinao, T., Boruah, H.P.D., Mahindroo, N., 2022. Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges. Biomed. Pharmacother. 146, 112488. https://doi.org/10.1016/j.biopha.2021.112488
Paranjape, T., Slack, F.J., Weidhaas, J.B., 2009. MicroRNAs: tools for cancer diagnostics. Gut 58, 1546–1554. https://doi.org/10.1136/gut.2009.179531
Pernía, O., Belda-Iniesta, C., Pulido, V., Cortes-Sempere, M., Rodriguez, C., Vera, O., Soto, J., Jiménez, J., Taus, A., Rojo, F., Arriola, E., Rovira, A., Albanell, J., Macías, M.T., de Castro, J., Perona, R., Ibañez de Caceres, I., 2014. Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy. Epigenetics 9, 1446–1453. https://doi.org/10.4161/15592294.2014.971626
Poddubskaya, E., Bondarenko, A., Boroda, A., Zotova, E., Glusker, A., Sletina, S., Makovskaia, L., Kopylov, P., Sekacheva, M., Moisseev, A., Baranova, M., 2019. Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors. Front. Oncol. 9, 1026. https://doi.org/10.3389/fonc.2019.01026
Prigent, C., Dimitrov, S., 2003. Phosphorylation of serine 10 in histone H3, what for? J. Cell Sci. 116, 3677–3685. https://doi.org/10.1242/jcs.00735
Provencio, M., Torrente, M., Calvo, V., Gutiérrez, L., Pérez-Callejo, D., Pérez-Barrios, C., Barquín, M., Royuela, A., Rodriguez-Alfonso, B., Sotelo, M., Cruz-Bermúdez, J.L., Mendez, M., Cruz-Bermúdez, A., Romero, A., 2017. Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment. Oncotarget 8, 60291–60298. https://doi.org/10.18632/oncotarget.20016
Provencio, M., Torrente, M., Calvo, V., Pérez-Callejo, D., Gutiérrez, L., Franco, F., Pérez-Barrios, C., Barquín, M., Royuela, A., García-García, F., Bueno, C., Garcia-Grande, A., Camps, C., Massuti, B., Sotomayor, E., Romero, A., 2018. Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients. Oncotarget 9, 488–494. https://doi.org/10.18632/oncotarget.22470
Pruneri, G., De Braud, F., Sapino, A., Aglietta, M., Vecchione, A., Giusti, R., Marchiò, C., Scarpino, S., Baggi, A., Bonetti, G., Franzini, J.M., Volpe, M., Jommi, C., 2021. Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? PharmacoEconomics - Open 5, 285–298. https://doi.org/10.1007/s41669-020-00249-0
Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P.A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T.M., Ky, B., Štěrba, M., Cardinale, D., Cohen‐Solal, A., Tocchetti, C.G., Farmakis, D., Bergler‐Klein, J., Anker, M.S., Von Haehling, S., Belenkov, Y., Iakobishvili, Z., Maack, C., Ciardiello, F., Ruschitzka, F., Coats, A.J.S., Seferovic, P., Lainscak, M., Piepoli, M.F., Chioncel, O., Bax, J., Hulot, J., Skouri, H., Hägler‐Laube, E.S., Asteggiano, R., Fernandez, T.L., Boer, R.A., Lyon, A.R., 2020. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the CARDIO‐ONCOLOGY STUDY GROUP of the HEART FAILURE ASSOCIATION and the CARDIO‐ONCOLOGY COUNCIL OF THE EUROPEAN SOCIETY OF CARDIOLOGY. Eur. J. Heart Fail. 22, 1966–1983. https://doi.org/10.1002/ejhf.2017
Qu, J., Li, M., Zhong, W., Hu, C., 2015. Prognostic role of microRNA-25 in cancers: evidence from a meta-analysis. Int. J. Clin. Exp. Med. 8, 12921–12927.
Quan, J., Gao, Y., Yang, Z., Chen, H., Xian, J., Zhang, S., Zou, Q., Zhang, L., 2015. Quantitative Detection of Circulating Nucleophosmin Mutations DNA in the Plasma of Patients with Acute Myeloid Leukemia. Int. J. Med. Sci. 12, 17–22. https://doi.org/10.7150/ijms.10144
Rasmussen, S.L., Krarup, H.B., Sunesen, K.G., Pedersen, I.S., Madsen, P.H., Thorlacius-Ussing, O., 2016. Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review. Colorectal Dis. 18, 549–561. https://doi.org/10.1111/codi.13336
Ray, P., Manach, Y.L., Riou, B., Houle, T.T., Warner, D.S., 2010. Statistical Evaluation of a Biomarker. Anesthesiology 112, 1023–1040. https://doi.org/10.1097/ALN.0b013e3181d47604
Rebel, V.I., Kung, A.L., Tanner, E.A., Yang, H., Bronson, R.T., Livingston, D.M., 2002. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc. Natl. Acad. Sci. 99, 14789–14794. https://doi.org/10.1073/pnas.232568499
Rongna, M., Nannan, F., Xiao, Y., Hongyan, L., Xiaohong, Z., Oumin, S., Huan, Z., Shuo, Z., Lei, L., Min, Z., Ming, G., Herbert, Y., Biyun, Q., 2017. Promoter methylation of Wnt/β-Catenin signal inhibitor TMEM88 is associated with unfavorable prognosis of non-small cell lung cancer. Cancer Biol. Med. 14, 377. https://doi.org/10.20892/j.issn.2095-3941.2017.0061
Rowbotham, S.P., Li, F., Dost, A.F.M., Louie, S.M., Marsh, B.P., Pessina, P., Anbarasu, C.R., Brainson, C.F., Tuminello, S.J., Lieberman, A., Ryeom, S., Schlaeger, T.M., Aronow, B.J., Watanabe, H., Wong, K.K., Kim, C.F., 2018. H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression. Nat. Commun. 9, 4559. https://doi.org/10.1038/s41467-018-07077-1
Runz, S., Keller, S., Rupp, C., Stoeck, A., Issa, Y., Koensgen, D., Mustea, A., Sehouli, J., Kristiansen, G., Altevogt, P., 2007. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol. Oncol. 107, 563–571. https://doi.org/10.1016/j.ygyno.2007.08.064
Saleh, R., Toor, S.M., Sasidharan Nair, V., Elkord, E., 2020. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. Front. Immunol. 11, 1469. https://doi.org/10.3389/fimmu.2020.01469
Salvianti, F., Giuliani, C., Petrone, L., Mancini, I., Vezzosi, V., Pupilli, C., Pinzani, P., 2017. Integrity and Quantity of Total Cell-Free DNA in the Diagnosis of Thyroid Cancer: Correlation with Cytological Classification. Int. J. Mol. Sci. 18, 1350. https://doi.org/10.3390/ijms18071350
Sánchez-Herrero, E., Serna-Blasco, R., Robado de Lope, L., González-Rumayor, V., Romero, A., Provencio, M., 2022. Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. Front. Oncol. 12, 943253. https://doi.org/10.3389/fonc.2022.943253
Sato, K., Tsuchihara, K., Fujii, S., Sugiyama, M., Goya, T., Atomi, Y., Ueno, T., Ochiai, A., Esumi, H., 2007. Autophagy Is Activated in Colorectal Cancer Cells and Contributes to the Tolerance to Nutrient Deprivation. Cancer Res. 67, 9677–9684. https://doi.org/10.1158/0008-5472.CAN-07-1462
Sawyers, C.L., 2008. The cancer biomarker problem. Nature 452, 548–552. https://doi.org/10.1038/nature06913
Schwarzenbach, H., Hoon, D.S.B., Pantel, K., 2011. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426–437. https://doi.org/10.1038/nrc3066
Seligson, D.B., Horvath, S., McBrian, M.A., Mah, V., Yu, H., Tze, S., Wang, Q., Chia, D., Goodglick, L., Kurdistani, S.K., 2009. Global Levels of Histone Modifications Predict Prognosis in Different Cancers. Am. J. Pathol. 174, 1619–1628. https://doi.org/10.2353/ajpath.2009.080874
Serpas, L., Chan, R.W.Y., Jiang, P., Ni, M., Sun, K., Rashidfarrokhi, A., Soni, C., Sisirak, V., Lee, W.-S., Cheng, S.H., Peng, W., Chan, K.C.A., Chiu, R.W.K., Reizis, B., Lo, Y.M.D., 2019. Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proc. Natl. Acad. Sci. 116, 641–649. https://doi.org/10.1073/pnas.1815031116
Serratì, S., De Summa, S., Pilato, B., Petriella, D., Lacalamita, R., Tommasi, S., Pinto, R., 2016. Next-generation sequencing: advances and applications in cancer diagnosis. OncoTargets Ther. Volume 9, 7355–7365. https://doi.org/10.2147/OTT.S99807
Shah, J.S., Soon, P.S., Marsh, D.J., 2016. Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs. PLOS ONE 11, e0153200. https://doi.org/10.1371/journal.pone.0153200
Sharma, A., Liu, H., Herwig-Carl, M.C., Chand Dakal, T., Schmidt-Wolf, I.G.H., 2021. Epigenetic Regulatory Enzymes: mutation Prevalence and Coexistence in Cancers. Cancer Invest. 39, 257–273. https://doi.org/10.1080/07357907.2021.1872593
Shilatifard, A., 2012. The COMPASS Family of Histone H3K4 Methylases: Mechanisms of Regulation in Development and Disease Pathogenesis. Annu. Rev. Biochem. 81, 65–95. https://doi.org/10.1146/annurev-biochem-051710-134100
Simonian, M., Mosallayi, M., Mirzaei, H., 2018. Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker. J. Cancer Res. Ther. 14, 475. https://doi.org/10.4103/0973-1482.175428
Søes, S., Daugaard, I.L., Sørensen, B.S., Carus, A., Mattheisen, M., Alsner, J., Overgaard, J., Hager, H., Hansen, L.L., Kristensen, L.S., 2014. Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. Oncoscience 1, 367–374. https://doi.org/10.18632/oncoscience.42
Stephan, F., Marsman, G., Bakker, L.M., Bulder, I., Stavenuiter, F., Aarden, L.A., Zeerleder, S., 2014. Cooperation of Factor VII-Activating Protease and Serum DNase I in the Release of Nucleosomes From Necrotic Cells: FSAP and DNase I Cooperation in Necrotic Cell Release of Nucleosomes. Arthritis Rheumatol. 66, 686–693. https://doi.org/10.1002/art.38265
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 71, 209–249. https://doi.org/10.3322/caac.21660
Šutić, M., Vukić, A., Baranašić, J., Försti, A., Džubur, F., Samaržija, M., Jakopović, M., Brčić, L., Knežević, J., 2021. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. J. Pers. Med. 11, 1102. https://doi.org/10.3390/jpm11111102
Svoronos, A.A., Engelman, D.M., Slack, F.J., 2016. OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Res. 76, 3666–3670. https://doi.org/10.1158/0008-5472.CAN-16-0359
Sze, C.C., Shilatifard, A., 2016. MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer. Cold Spring Harb. Perspect. Med. 6, a026427. https://doi.org/10.1101/cshperspect.a026427
Tanaka, Y., Kamohara, H., Kinoshita, K., Kurashige, J., Ishimoto, T., Iwatsuki, M., Watanabe, M., Baba, H., 2013. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma: Exosomal MicroRNA-21 Expression in ESCC. Cancer 119, 1159–1167. https://doi.org/10.1002/cncr.27895
Tang, L., Chen, Y., Peng, X., Zhou, Y., Jiang, H., Wang, G., Zhuang, W., 2020. Identification and Validation of Potential Pathogenic Genes and Prognostic Markers in ESCC by Integrated Bioinformatics Analysis. Front. Genet. 11, 521004. https://doi.org/10.3389/fgene.2020.521004
Tang, Q., Cheng, J., Cao, X., Surowy, H., Burwinkel, B., 2016. Blood-based DNA methylation as biomarker for breast cancer: a systematic review. Clin. Epigenetics 8, 115. https://doi.org/10.1186/s13148-016-0282-6
Tavares, N.T., Gumauskaitė, S., Lobo, J., Jerónimo, C., Henrique, R., 2022. DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand? Cancers 14, 2918. https://doi.org/10.3390/cancers14122918
Thierry, A.R., El Messaoudi, S., Gahan, P.B., Anker, P., Stroun, M., 2016. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 35, 347–376. https://doi.org/10.1007/s10555-016-9629-x
Tkachev, V., Sorokin, M., Garazha, A., Borisov, N., Buzdin, A., 2020. Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data. Methods Mol. Biol. Clifton NJ 2063, 235–255. https://doi.org/10.1007/978-1-0716-0138-9_17
Toiyama, Y., Takahashi, M., Hur, K., Nagasaka, T., Tanaka, K., Inoue, Y., Kusunoki, M., Boland, C.R., Goel, A., 2013. Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer. JNCI J. Natl. Cancer Inst. 105, 849–859. https://doi.org/10.1093/jnci/djt101
Townsend, M.H., Shrestha, G., Robison, R.A., O’Neill, K.L., 2018. The expansion of targetable biomarkers for CAR T cell therapy. J. Exp. Clin. Cancer Res. 37, 163. https://doi.org/10.1186/s13046-018-0817-0
Umetani, N., Mori, T., Koyanagi, K., Shinozaki, M., Kim, J., Giuliano, A.E., Hoon, D.S.B., 2005. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 24, 4721–4727. https://doi.org/10.1038/sj.onc.1208538
Vagner, T., Spinelli, C., Minciacchi, V.R., Balaj, L., Zandian, M., Conley, A., Zijlstra, A., Freeman, M.R., Demichelis, F., De, S., Posadas, E.M., Tanaka, H., Di Vizio, D., 2018. Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J. Extracell. Vesicles 7, 1505403. https://doi.org/10.1080/20013078.2018.1505403
Verma, Mukesh, Patel, P., Verma, Mudit, 2011. Biomarkers in Prostate Cancer Epidemiology. Cancers 3, 3773–3798. https://doi.org/10.3390/cancers3043773
Wang, C.-Y., Filippakopoulos, P., 2015. Beating the odds: BETs in disease. Trends Biochem. Sci. 40, 468–479. https://doi.org/10.1016/j.tibs.2015.06.002
Wood, A., Schneider, J., Dover, J., Johnston, M., Shilatifard, A., 2003. The Paf1 Complex Is Essential for Histone Monoubiquitination by the Rad6-Bre1 Complex, Which Signals for Histone Methylation by COMPASS and Dot1p. J. Biol. Chem. 278, 34739–34742. https://doi.org/10.1074/jbc.C300269200
Wrage, M., Hagmann, W., Kemming, D., Uzunoglu, F.G., Riethdorf, S., Effenberger, K., Westphal, M., Lamszus, K., Kim, S.-Z., Becker, N., Izbicki, J.R., Sandoval, J., Esteller, M., Pantel, K., Risch, A., Wikman, H., 2015. Identification of HERC5 and its potential role in NSCLC progression: HERC5 in Micrometastatic Lung Cancer. Int. J. Cancer 136, 2264–2272. https://doi.org/10.1002/ijc.29298
Wu, F., Lu, M., Qu, L., Li, D.-Q., Hu, C.-H., 2015. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 8, 5457–5463.
Wu, K.-L., Tsai, Y.-M., Lien, C.-T., Kuo, P.-L., Hung, J.-Y., 2019. The Roles of MicroRNA in Lung Cancer. Int. J. Mol. Sci. 20, 1611. https://doi.org/10.3390/ijms20071611
Wu, Y., Li, Q., Zhang, R., Dai, X., Chen, W., Xing, D., 2021. Circulating microRNAs: Biomarkers of disease. Clin. Chim. Acta 516, 46–54. https://doi.org/10.1016/j.cca.2021.01.008
Xhemalce, B., Dawson, M.A., Bannister, A.J., 2011. Histone Modifications, in: Meyers, R.A. (Ed.), Encyclopedia of Molecular Cell Biology and Molecular Medicine. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, p. mcb.201100004. https://doi.org/10.1002/3527600906.mcb.201100004
Xue, C., Zhao, Y., Li, L., 2020. Advances in RNA cytosine-5 methylation: detection, regulatory mechanisms, biological functions and links to cancer. Biomark. Res. 8, 43. https://doi.org/10.1186/s40364-020-00225-0
Yang, C.-C., Hung, P.-S., Wang, P.-W., Liu, C.-J., Chu, T.-H., Cheng, H.-W., Lin, S.-C., 2011. miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma: miR-181 and OSCC. J. Oral Pathol. Med. 40, 397–404. https://doi.org/10.1111/j.1600-0714.2010.01003.x
Yang, J., Hui, Y., Zhang, Y., Zhang, M., Ji, B., Tian, G., Guo, Y., Tang, M., Li, L., Guo, B., Ma, T., 2021. Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer. Front. Oncol. 11, 725938. https://doi.org/10.3389/fonc.2021.725938
Yang, Y., Zhang, M., Wang, Y., 2022. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J. Natl. Cancer Cent. 2, 277–290. https://doi.org/10.1016/j.jncc.2022.09.002
Yao, S., Wu, D., Chen, J., Wang, P., Lv, X., Huang, J., 2019. Hypermethylation of the G protein‐coupled receptor kinase 6 (GRK6) promoter inhibits binding of C/EBPα, and GRK6 knockdown promotes cell migration and invasion in lung adenocarcinoma cells. FEBS Open Bio 9, 605–617. https://doi.org/10.1002/2211-5463.12606
Yu, J., Hou, M., Pei, T., 2020. FAM83A is a Prognosis Signature and Potential Oncogene of Lung Adenocarcinoma. DNA Cell Biol. 39, 890–899. https://doi.org/10.1089/dna.2019.4970
Zhang, K., Wang, J., Yang, L., Yuan, Y.-C., Tong, T.R., Wu, J., Yun, X., Bonner, M., Pangeni, R., Liu, Z., Yuchi, T., Kim, J.Y., Raz, D.J., 2018. Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer. Mol. Cancer 17, 153. https://doi.org/10.1186/s12943-018-0896-8
Zhang, Y., Xu, R., Li, G., Xie, X., Long, J., Wang, H., 2012. Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells. Tumor Biol. 33, 1915–1925. https://doi.org/10.1007/s13277-012-0452-x
Zhao, X., Wang, A., Walter, V., Patel, N.M., Eberhard, D.A., Hayward, M.C., Salazar, A.H., Jo, H., Soloway, M.G., Wilkerson, M.D., Parker, J.S., Yin, X., Zhang, G., Siegel, M.B., Rosson, G.B., Earp, H.S., Sharpless, N.E., Gulley, M.L., Weck, K.E., Hayes, D.N., Moschos, S.J., 2015. Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC. PLOS ONE 10, e0129280. https://doi.org/10.1371/journal.pone.0129280
Zhao, Z., Shilatifard, A., 2019. Epigenetic modifications of histones in cancer. Genome Biol. 20, 245. https://doi.org/10.1186/s13059-019-1870-5
Zhu, B., Zheng, Y., Pham, A.-D., Mandal, S.S., Erdjument-Bromage, H., Tempst, P., Reinberg, D., 2005. Monoubiquitination of Human Histone H2B: The Factors Involved and Their Roles in HOX Gene Regulation. Mol. Cell 20, 601–611. https://doi.org/10.1016/j.molcel.2005.09.025
Zorofchian, S., Lu, G., Zhu, J.-J., Duose, D.Y., Windham, J., Esquenazi, Y., Ballester, L.Y., 2018. Detection of the MYD88 p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma. Front. Oncol. 8, 382. https://doi.org/10.3389/fonc.2018.00382
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Andika Dwi Mahendra, Muhammad Hatta Prabowo, Aisyah Fitriannisa Prawiningrum
This work is licensed under a Creative Commons Attribution 4.0 International License.
